Similar articles

• The "black box" warning and allergy drugs.

  Aaronson DW. Aaronson DW. J Allergy Clin Immunol. 2006 Jan;117(1):40-4. doi: 10.1016/j.jaci.2005.08.060. J Allergy Clin Immunol. 2006. PMID: 16387582
• Primum non nocere and "black box" warnings.

  Pearlman DS. Pearlman DS. J Allergy Clin Immunol. 2006 Jan;117(1):30-1. doi: 10.1016/j.jaci.2005.09.030. Epub 2005 Dec 2. J Allergy Clin Immunol. 2006. PMID: 16387580 No abstract available.
• Topical calcineurin inhibitors labeling: putting the "box" in perspective.

  Stern RS. Stern RS. Arch Dermatol. 2006 Sep;142(9):1233-5. doi: 10.1001/archderm.142.9.1233. Arch Dermatol. 2006. PMID: 16983018 No abstract available.
• The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force.

  Berger TG, Duvic M, Van Voorhees AS, VanBeek MJ, Frieden IJ; American Academy of Dermatology Association Task Force. Berger TG, et al. J Am Acad Dermatol. 2006 May;54(5):818-23. doi: 10.1016/j.jaad.2006.01.054. J Am Acad Dermatol. 2006. PMID: 16635663 Review. No abstract available.
• [What is reliable in the therapy of the bronchial asthma?].

  Kessler GF. Kessler GF. Internist (Berl). 1975 Dec;16(12):594-601. Internist (Berl). 1975. PMID: 2564 Review. German. No abstract available.